All Oncology News

The European Commission has approved everolimus (Afinitor) for use as treatment for patients with progressive, unresectable or metastatic, well-differentiated nonfunctional gastrointestinal or lung neuroendocrine tumors.

Jennifer Brown, MD, discusses the findings and impact of the RESONATE and RESONATE-2 trials, as well as the role of ibrutinib in older and younger patients with chronic lymphocytic leukemia in both the frontline and relapsed settings.

A long-term analysis has shown that approximately one-fifth of patients with BRAF V600-mutant melanoma who were treated with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) remained progression-free after 3 years, suggesting a plateau of the survival curve.

Tanios Bekaii-Saab, MD, discusses the use of both regorafenib and TAS-102, as well as the potential role immunotherapy could have within colorectal cancer.

The global cost of cancer therapies shot up to $107 billion in 2015, an 11.5% rise from the $100 billion 2014 total for oncology therapeutics and supportive care drugs.

The FDA has approved new diagnostic tests for the detection of somatostatin receptor-positive neuroendocrine tumors and for EGFR mutations from blood samples for patients with non–small cell lung cancer.

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

The European Commission has approved ibrutinib (Imbruvica) as a first-line treatment for patients with chronic lymphocytic leukemia.

The FDA has granted a priority review to a new drug application for telotristat etiprate as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors.

Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.

Phase I trial results demonstrate that abemaciclib, a CDK 4/6 inhibitor, had significant clinical activity and an overall response rate of 31% in patients with hormone receptor-positive breast cancer.

Yong-Chen William Lu, PhD, discusses a phase I dose-escalation study investigating the genetically engineered CD4 T cells' ability to target the MAGE-A3 protein.

Frontline treatment with fulvestrant improved progression-free survival versus anastrozole for postmenopausal patients with locally-advanced or metastatic HR-positive breast cancer.

The EMA's Committee for Medicinal Products for Human Use has granted a positive opinion to brentuximab vedotin (Adcetris) for use as a consolidation therapy following autologous stem cell transplantation in patients with CD30-positive Hodgkin lymphoma at risk of relapse or progression.

Carfilzomib (Kyprolis) has received a positive recommendation from the EMA's Committee for Medicinal Products for Human Use for use in combination with dexamethasone alone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Combining obinutuzumab (Gazyva) with chemotherapy in the first-line setting significantly reduced the risk of disease progression versus rituximab (Rituxan) plus chemotherapy in patients with follicular lymphoma.

The radioactive imaging agent, fluciclovine F18 (Axumin), was approved by the FDA for use in positron emission tomography scans in men with suspected recurrence of prostate cancer whose prostate-specific antigen levels rise following prior treatment.

Keith C. Bible, MD, PhD, discusses novel treatments he is excited about, the role of lenvatinib, and what the future may hold for thyroid cancer treatment.

James Melotek, MD, discusses two clinical trials looking at the impact of cetuximab in patients with squamous cell carcinoma of the head and neck.

Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Robert Ferris, MD, PhD, explains the potential of nivolumab, its future, and its limitations in the treatment of patients with head and neck cancer.

Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.

Cabozantinib (Cabometyx) significantly improved progression-free survival compared with sunitinib (Sutent) in treatment-naive patients with advanced renal cell carcinoma in the phase II CABOSUN trial.

The European Commission has granted conditional marketing approval to daratumumab (Darzalex) for the treatment of patients with relapsed/refractory multiple myeloma previously treated with a proteasome inhibitor and an immunomodulatory agent who progressed on their last therapy.

Kevin Hughes, MD, discusses the pros and cons of radiation therapy in elderly patients with breast cancer, as well as luminal A patients, and the overall changing role of the treatment in the field.

The use of immunohistochemistry could be a more cost- and time-efficient first-line screening method for identifying ROS1 gene rearrangements to predict eligibility for crizotinib (Xalkori) for patients with non–small cell lung cancer compared with fluorescence in-situ hybridization.

Luke Nordquist, MD, discusses a study investigating a higher dose of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and the ongoing potential of the agent in treating the disease.

The FDA has granted a breakthrough therapy designation to CPX-351 (Vyxeos) as a treatment for patients with therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

Luca Gianni, MD, discusses the significance of the long-term NeoSphere trial results and how the regimen is already impacting the landscape of HER2-positive breast cancer.

Sunil Verma, MD, discusses the current landscape in HER2-positive breast cancer and his views on neoadjuvant treatment options.